查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1649459

电脑辅助药物研发市场 - 2025-2030 年预测

Computer-Aided Drug Discovery Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

电脑辅助药物发现市场预计将从 2025 年的 59.55 亿美元成长到 2030 年的 103.06 亿美元，预测期内的复合年增长率为 11.59%。

药物研发是一个漫长而复杂的过程，但数位转型正在使製药业更有效率、更有效率。电脑辅助药物发现、自动化数位化的整合对于提高品质、降低成本和缩短时间至关重要。动态在电脑辅助药物发现的应用使得生物和化学系统的In Silico建模具有高度准确性，有助于识别新型候选药物。慢性病的增加推动了快速药物开发的需求，进一步推动了电脑辅助药物发现市场的成长。根据美国国家卫生统计中心的数据，2023年美国将有1,958,310例新发癌症病例，609,820例死于癌症，因此迫切需要解决这个健康问题。

电脑辅助药物发现市场驱动因素：

  • 人工智慧在药物研发的应用日益广泛：寻找新药十分复杂，耗时较长，需要先进的解决方案。确定能够有效结合特定疾病相关标靶的合适化合物需要筛检大量分子。人工智慧正在透过知识图谱、In Silico目标识别和目标排序等技术发现潜在化合物，从而改变这一过程，促进更精准的治疗方法的开发。

例如，2023年12月，默克推出了AIDDISON，这是一个整合生成式AI、机器学习和电脑辅助药物设计的突破性药物发现软体平台。该软体透过整合 Synthia™ 逆合成 API 弥合了虚拟分子设计与现实世界可製造性之间的差距。 AIDDISON 基于 20 多年药物研发中累积的经过检验的资料集，根据药物成功所必需的关键特性（如无毒性、溶解度和稳定性），分析了超过 600 亿种可能性。像 AIDDISON 这样的人工智慧和机器学习模型有可能显着提高新药的成功率，同时将与药物研发相关的成本降低高达 70%。

影响电脑辅助药物发现市场的地理趋势：

  • 北美显着成长：由于精神健康障碍盛行率上升、人工智慧技术的进步以及远端医疗解决方案的接受度不断提高等多种因素，预计美国的电脑辅助药物发现市场将显着增长。自 COVID-19 疫情加剧这些挑战以来，对焦虑、忧郁症和创伤后压力症候群等心理健康问题的有效治疗方案的需求激增。

随着传统医疗保健系统难以满足需求，人工智慧技术正在成为提供可扩展、可存取的心理健康护理的可行解决方案。美国政府已经认识到人工智慧在医疗保健领域的潜力，并启动了促进其发展的计划。例如，美国人工智慧倡议旨在将美国定位为人工智慧领域的领先者，并正在製定人工智慧在各个领域的应用指南。此外，心理健康技术的丰厚融资机会正在吸引公共和私营部门的投资。强大的医疗保健IT基础设施加上公众对心理健康问题日益增强的认识，创造了一个有利于 AI 解决方案快速扩展的环境。摘要，由于人工智慧应用在药物发现过程中的日益普及、全球对慢性病有效治疗方法的需求不断增长、政府支持措施促进医疗技术创新，以及有利的区域趋势（尤其是北美）正在加强这一不断扩大的市场环境，电脑辅助药物发现市场将见证显着增长。

为什么要购买这份报告？

  • 深刻分析：获得深入的市场洞察，涵盖主要和新兴地区，重点关注客户群、政府政策和社会经济因素、消费者偏好、垂直行业和其他子区隔。
  • 竞争格局：了解全球主要企业所采用的策略策略，并了解正确策略带来的潜在市场渗透率。
  • 市场趋势和驱动因素：探索动态因素和关键市场趋势以及它们将如何影响未来的市场发展。
  • 可行的建议：利用洞察力做出策略决策，在动态环境中开闢新的业务流和收益。
  • 适合广泛用户：对于新兴企业、科学研究机构、顾问公司、中小企业和大型企业来说都是有益且具成本效益的。

它有什么用途？

产业与市场考量、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本支出决策、法律规范与影响、新产品开发、竞争影响

研究范围

  • 2022 年至 2030 年的历史资料与预测
  • 成长机会、挑战、供应链前景、法规结构、客户行为和趋势分析
  • 竞争定位、策略和市场占有率分析
  • 收益成长和预测分析包括国家在内的细分市场和地区
  • 公司概况（尤其是主要趋势）

电脑辅助药物发现市场区隔如下：

按类型

  • Structure-Based Drug Design
  • Ligand-Based Drug Design
  • Sequence-Based Approaches

按治疗领域

  • 肿瘤学
  • 神经病学
  • 循环系统
  • 呼吸系统
  • 其他的

按最终用途

  • 製药公司
  • 生技公司
  • 研究所

按地区

  • 北美洲
  • 美国
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 南美洲其他地区
  • 欧洲
  • 英国
  • 德国
  • 法国
  • 义大利
  • 西班牙
  • 其他欧洲国家
  • 中东 中东和非洲
  • 沙乌地阿拉伯
  • UAE
  • 其他中东和非洲地区
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 台湾
  • 泰国
  • 印尼
  • 其他亚太地区

目录

第 1 章 简介

  • 市场概况
  • 市场定义
  • 研究范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益

第二章调查方法

  • 研究设计
  • 研究过程
  • 资料检验

第三章执行摘要

  • 主要发现
  • 分析师观点

第四章 市场动态

  • 市场驱动因素
  • 市场限制
  • 波特五力分析
  • 产业价值链分析

5. 电脑辅助药物发现市场（按类型）

  • 介绍
  • Structure-Based Drug Design
  • Ligand-Based Drug Design
  • Sequence-Based Approaches

6. 电脑辅助药物发现市场（依治疗领域）

  • 介绍
  • 肿瘤学
  • 神经病学
  • 循环系统
  • 呼吸系统
  • 其他的

7. 电脑辅助药物研发市场（依最终用途划分）

  • 介绍
  • 製药公司
  • 生技公司
  • 研究所

8. 电脑辅助药物发现市场（按地区）

  • 世界概况
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲国家
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 台湾
    • 泰国
    • 印尼
    • 其他亚太地区

第九章竞争格局及分析

  • 主要企业和策略分析
  • 新兴企业和市场盈利
  • 合併、收购、协议和合作
  • 竞争仪錶板

第十章 公司简介

  • Aragen Life Sciences Pvt. Ltd.
  • Bioduro-Sundia
  • BOC Sciences
  • Aris Pharmaceuticals, Inc.
  • AstraZeneca
  • Schrodinger, Inc.
  • Bayer AG
  • Charles River Laboratories
  • Albany Molecular Research Inc.（Curia Global, Inc.）
  • Insilico Medicine
简介目录
Product Code: KSI061617235

The computer-aided drug discovery market is projected to grow at a CAGR of 11.59% over the forecast period, increasing from US$5.955 billion in 2025 to US$10.306 billion by 2030.

Drug discovery is a lengthy and complex process, but digital transformation is enhancing efficiency and effectiveness in the pharmaceutical industry. The integration of computer-aided drug discovery, automation, and digitization has become essential for improving quality, reducing costs, and shortening timelines. As resource constraints and changing scenarios arise, automation and digitization are key drivers of business growth.The application of quantum mechanics in computer-aided drug discovery has enabled highly accurate in-silico modeling of biological and chemical systems, facilitating the identification of novel drug candidates. The rising incidence of chronic diseases has intensified the need for rapid drug development, further boosting the growth of the computer-aided drug discovery market. According to the National Center for Health Statistics, it is projected that there will be 1,958,310 new cancer cases and 609,820 cancer deaths in the United States in 2023, underscoring the urgency of addressing these health challenges.

Drivers of the Computer-Aided Drug Discovery Market:

  • Expanding Use of Artificial Intelligence in Drug Discovery: The complexity and time-consuming nature of new drug discovery necessitate advanced solutions. Identifying suitable compounds that can effectively bind to specific disease-related targets requires screening vast numbers of molecules. AI is transforming this process by enabling the discovery of potential compounds through technologies such as knowledge graphs, in-silico target identification, and target ranking, which expedite treatment development with greater precision.

For instance, in December 2023, Merck launched AIDDISON, a groundbreaking drug discovery software platform that integrates generative AI, machine learning, and computer-aided drug design. This software bridges the gap between virtual molecule design and real-world manufacturability through Synthia(TM) retrosynthesis API integration. AIDDISON analyzes over 60 billion possibilities based on key properties essential for successful drugs-such as non-toxicity, solubility, and stability-drawing on more than two decades of validated datasets from pharmaceutical R&D.AI and machine learning models like AIDDISON significantly enhance the success rate of new patient therapies while potentially reducing costs associated with drug discovery by up to 70%.

Geographical Trends Shaping the Computer-Aided Drug Discovery Market:

  • Significant Growth in North America: The computer-aided drug discovery market is poised for substantial growth in the United States due to several factors, including a rising prevalence of mental health disorders, advancements in AI technologies, and increasing acceptance of telehealth solutions. The demand for effective treatment options for mental health issues such as anxiety, depression, and PTSD has surged since the COVID-19 pandemic exacerbated these challenges.

As traditional healthcare systems struggle to keep up with demand, AI technologies are emerging as viable solutions to provide scalable and accessible mental health care. AI-driven platforms can analyze large datasets to offer personalized therapy and real-time emotional support.The U.S. government has recognized AI's potential in healthcare and has initiated programs to promote its development. For example, the American AI Initiative aims to position the U.S. as a leader in artificial intelligence by establishing guidelines for its application across various sectors. Additionally, favorable funding opportunities for mental health technology have attracted investments from both public and private sectors.The combination of a robust healthcare IT infrastructure and growing public awareness about mental health issues creates an environment conducive to rapid expansion of AI solutions.In summary, the computer-aided drug discovery market is set for significant growth driven by increased adoption of AI applications in drug discovery processes, rising global demand for effective treatments for chronic diseases, supportive governmental initiatives promoting innovation in healthcare technologies, and favorable geographical trends-especially within North America-that enhance this expanding market landscape.

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

Computer-Aided Drug Discovery Market has been segmented as following:

By Type

  • Structure-Based Drug Design
  • Ligand-Based Drug Design
  • Sequence-Based Approaches

By Therapeutic Area

  • Oncology
  • Neurology
  • Cardiovascular Disease
  • Respiratory Disease
  • Others

By End User

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Research Laboratories

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Rest of South America
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Rest of the Middle East and Africa
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Rest of Asia-Pacific

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Process
  • 2.3. Data Validation

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. Analyst View

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Supplier
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. COMPUTER-AIDED DRUG DISCOVERY MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Structure-Based Drug Design
  • 5.3. Ligand-Based Drug Design
  • 5.4. Sequence-Based Approaches

6. COMPUTER-AIDED DRUG DISCOVERY MARKET BY THERAPEUTIC AREA

  • 6.1. Introduction
  • 6.2. Oncology
  • 6.3. Neurology
  • 6.4. Cardiovascular Disease
  • 6.5. Respiratory Disease
  • 6.6. Others

7. COMPUTER-AIDED DRUG DISCOVERY MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Pharmaceutical Companies
  • 7.3. Biotechnology Companies
  • 7.4. Research Laboratories

8. COMPUTER-AIDED DRUG DISCOVERY MARKET BY GEOGRAPHY

  • 8.1. Global Overview
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Rest of South America
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Italy
    • 8.4.5. Spain
    • 8.4.6. Rest of Europe
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. United Arab Emirates
    • 8.5.3. Rest of the Middle East and Africa
  • 8.6. Asia-Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Taiwan
    • 8.6.6. Thailand
    • 8.6.7. Indonesia
    • 8.6.8. Rest of Asia-Pacific

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Emerging Players and Market Lucrativeness
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Aragen Life Sciences Pvt. Ltd.
  • 10.2. Bioduro-Sundia
  • 10.3. BOC Sciences
  • 10.4. Aris Pharmaceuticals, Inc.
  • 10.5. AstraZeneca
  • 10.6. Schrodinger, Inc.
  • 10.7. Bayer AG
  • 10.8. Charles River Laboratories
  • 10.9. Albany Molecular Research Inc. (Curia Global, Inc.)
  • 10.10. Insilico Medicine